[go: up one dir, main page]

AR096893A1 - Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro - Google Patents

Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro

Info

Publication number
AR096893A1
AR096893A1 ARP140102578A ARP140102578A AR096893A1 AR 096893 A1 AR096893 A1 AR 096893A1 AR P140102578 A ARP140102578 A AR P140102578A AR P140102578 A ARP140102578 A AR P140102578A AR 096893 A1 AR096893 A1 AR 096893A1
Authority
AR
Argentina
Prior art keywords
composition
vegf
antagonist
retinotherapy
endotelium
Prior art date
Application number
ARP140102578A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR096893A1 publication Critical patent/AR096893A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Una composición para tratar un bebé que tiene un trastorno neovascular de la retina que comprende un antagonista del VEGF que ya sea no ingrese o sea eliminado rápidamente de la circulación sistémica del bebé.
ARP140102578A 2013-07-11 2014-07-11 Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro AR096893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11

Publications (1)

Publication Number Publication Date
AR096893A1 true AR096893A1 (es) 2016-02-03

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102578A AR096893A1 (es) 2013-07-11 2014-07-11 Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro

Country Status (14)

Country Link
US (1) US20160159893A1 (es)
EP (1) EP3019527A2 (es)
JP (1) JP2016523956A (es)
KR (1) KR20160030504A (es)
CN (1) CN105377890A (es)
AR (1) AR096893A1 (es)
AU (3) AU2014288847A1 (es)
BR (1) BR112016000282A2 (es)
CA (1) CA2917813A1 (es)
HK (1) HK1221231A1 (es)
MX (1) MX2016000385A (es)
RU (1) RU2676303C2 (es)
TW (1) TW201536317A (es)
WO (1) WO2015004626A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
AU2010271105C1 (en) 2009-01-12 2014-08-21 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CA2998673C (en) 2015-09-23 2023-12-12 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
EP3397271B1 (en) 2015-12-30 2021-11-03 Marshall University Research Corporation Compositions and methods for treating retinopathy
IL260323B2 (en) 2015-12-30 2025-01-01 Kodiak Sciences Inc Antibodies and their conjugates
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
CA3138682A1 (en) 2019-04-29 2020-11-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
PT1660057E (pt) * 2003-08-27 2012-08-02 Ophthotech Corp Terapia de associação para o tratamento de distúrbios neovasculares oculares
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
ES2971647T3 (es) * 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
KR20100100855A (ko) * 2007-11-07 2010-09-15 안트로제네시스 코포레이션 조산 합병증의 치료에 있어서의 제대혈의 용도
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
CN107011425B (zh) 2008-11-03 2021-01-01 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
WO2010127029A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
EP2768504A1 (en) * 2011-10-20 2014-08-27 Avienne Pharmaceuticals GmbH Compositions for controlling vascularization in ophthalmological and dermatological diseases
ES2881671T3 (es) * 2012-08-21 2021-11-30 Opko Pharmaceuticals Llc Formulaciones de liposomas

Also Published As

Publication number Publication date
RU2676303C2 (ru) 2018-12-27
AU2017204326A1 (en) 2017-07-13
WO2015004626A2 (en) 2015-01-15
KR20160030504A (ko) 2016-03-18
EP3019527A2 (en) 2016-05-18
RU2016104398A (ru) 2017-08-16
US20160159893A1 (en) 2016-06-09
JP2016523956A (ja) 2016-08-12
BR112016000282A2 (pt) 2017-12-12
TW201536317A (zh) 2015-10-01
AU2019206000A1 (en) 2019-08-01
CN105377890A (zh) 2016-03-02
CA2917813A1 (en) 2015-01-15
WO2015004626A3 (en) 2015-05-28
HK1221231A1 (zh) 2017-05-26
AU2014288847A1 (en) 2016-01-28
MX2016000385A (es) 2016-04-29
RU2016104398A3 (es) 2018-05-31

Similar Documents

Publication Publication Date Title
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AR111208A1 (es) ANTICUERPOS ANTI-PÉPTIDO b AMILOIDE N3PGLU Y SUS USOS
CL2017001188A1 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
EA201790398A1 (ru) Способы лечения заболевания печени
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
PH12015502469A1 (en) Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases
BR112015027477A2 (pt) método para tratamento de um transtorno de deglutição
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
PL3288588T3 (pl) Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
TW201613628A (en) Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders
CL2017000636A1 (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Legal Events

Date Code Title Description
FB Suspension of granting procedure